Evolus (NASDAQ: EOLS) reported Q4 EPS of ($0.33), $0.14 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $34.7 million versus the consensus estimate of $33.99 million.

GUIDANCE:

Evolus sees FY2022 revenue of $143-150 million, versus the consensus of $147.3 million.

• The company continues to expect total net revenues for full-year 2022 to be between $143 million and $150 million, representing strong year-over-year growth of 43% to 50%. This assumes a minimal sales contribution from international markets.
• The company expects its adjusted gross profit margin for the full year 2022 to be between 58% and 61%. Settlement royalty rates will decrease significantly in September 2022, which is expected to lift the adjusted gross profit margin to be between 68% to 71% for the fourth quarter of 2022.
• Non-GAAP operating expenses for 2022 are estimated to be between $135 million and $140 million, which consists mainly of continued investments in the growth of Jeuveau® in the U.S. plus Nuceiva® launch expenses in Europe. Non-GAAP operating expenses exclude product cost of sales, revaluation of the contingent royalty obligation expense, stock-based compensation expense, and depreciation and amortization expense.
• During the first quarter of 2022, the company expects to make its second lump-sum settlement payment of $15 million under the 2021 settlement agreements. The company will make its final settlement payment of $5 million in the first quarter of 2023.
• The company remains on track to commence the launch of Nuceiva® in Europe in the third quarter of 2022.

For earnings history and earnings-related data on Evolus (EOLS) click here.